IHP Underlines Benefits Of Manufacturing To Donate
Charity Explains ‘Strategic And Sustainable’ Advantages For Partners
Global health NGO International Health Partners has set out the reasons why manufacturing to donate represents a “strategic and sustainable” way for industry partners to collaborate with the charity on relief efforts.
You may also be interested in...
Partners Apotex and Ambio have announced approval of a second US teriparatide generic from the FDA, adding another Forteo rival to the market and removing hopes that Teva’s recently approved first generic could benefit from 180 days of market exclusivity. Further competition is also in the works with Amphastar awaiting FDA action on a further teriparatide ANDA.
Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.
Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.